Trial Profile
A Pilot Trial of NY-ESO-1-Specific T Cells in Patients With Metastatic NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Mipetresgene autoleucel (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- 10 Jan 2017 Status changed from active, no longer recruiting to completed.
- 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2016 Planned primary completion date changed from 1 Nov 2016 to 1 May 2017.